title: Adalimumab for refractory pulmonary sarcoidosis.
abstract: BACKGROUND
  Ireland has one of the highest prevalence of sarcoidosis globally. Currently anti-TNF treatment in sarcoidosis is considered on a case-by-case basis particularly in patients who have a sub-optimal response to corticosteroid therapy.
  
  
  OBJECTIVE
  We report our experience of Adalimumab in a series of refractory pulmonary sarcoidosis and discuss implications for treatment.
  
  
  CONCLUSIONS
  Symptomatic improvement was found in all patients as well as stabilisation or improvement in DLCO sb. Improvements in pulmonary function tests correlated well to radiological stage and length of disease.
authors.affiliation: School of Medicine and Medical Science, College of Life Sciences, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland. paul.minnis@ucd.ie.|National Pulmonary Fibrosis Referral Centre at St Vincent's University Hospital, Elm Park, Dublin, Ireland. paul.minnis@ucd.ie.
authors.forename: P A
authors.initials: PA
authors.lastname: Minnis
authors.affiliation: School of Medicine and Medical Science, College of Life Sciences, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland.
authors.forename: M
authors.initials: M
authors.lastname: Poland
authors.affiliation: School of Medicine and Medical Science, College of Life Sciences, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland.|National Pulmonary Fibrosis Referral Centre at St Vincent's University Hospital, Elm Park, Dublin, Ireland.
authors.forename: M P
authors.initials: MP
authors.lastname: Keane
authors.affiliation: Department of Medicine, Trinity Centre for Health Sciences, Tallaght Hospital, Tallaght, Dublin, Ireland.
authors.forename: S C
authors.initials: SC
authors.lastname: Donnelly
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D001688:Biological Products / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007494:Ireland; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D019141:Respiratory System Agents / Q000627:therapeutic use*; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D001688:Biological Products; D019141:Respiratory System Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
keywords: Adalimumab; Biologics; Pulmonary; Refractory; Sarcoidosis